Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: MDB stock price vs CNC: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CNC's multiple
Needs CNC P/S.
Implied fair value · at MDB's multiple
Needs MDB P/S.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
MONGODB, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
CENTENE CORPORATION · implied price per share
Bear
$118.61
Base
$138.46
Bull
$164.32
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe MDB can sustain 20%+ revenue growth while driving margins toward breakeven, then holding or accumulating can be justified because its 71.7% gross margin and -1.0% EBITDA margin offer far better operating leverage than CNC. If you expect growth to slow or margins to stall, then the current 11.0x P/S valuation looks difficult to defend versus CNC's much lower revenue multiple.
On a relative basis, MDB screens extremely expensive versus CNC: its P/S is 11.0x versus CNC at 0.2x, and EV/Revenue is 10.7x versus 0.1x. The stated CNC-implied price of $4.84 implies -98.6% downside from MDB's current price of $337.48, but that gap is driven by CNC being an insurer with very different revenue economics rather than a like-for-like comp.
Supporting Metrics
